We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through the clinic.
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...
Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...
The study also clarifies the functional role of the receptor's conserved sodium-binding pocket, showing that sodium egress strongly promotes activation-related conformational states, including a ...
Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a ...
ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, ...
Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results